Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carducci

Showing results (191-200 of 386) with videos related to

Pageof 39
Sort By:
Urologic Oncology|October 7, 2004
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancerDonald S Kaufman, Michael A Carducci, Tim M Kuzel, et al.
Cancer|September 22, 2007
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerMichael A Carducci, Fred Saad, Per-Anders Abrahamsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion scheduleM A Carducci, J Gilbert, M K Bowling, et al.
Urologic Oncology|September 22, 2014
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)Andrew J Armstrong, Reza Kaboteh, Michael A Carducci, et al.
Prostate Cancer and Prostatic Diseases|February 11, 2010
Does pre-existing diabetes affect prostate cancer prognosis? A systematic reviewC F Snyder, K B Stein, B B Barone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2017
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical OpinionKatherine S Virgo, Ethan Basch, D Andrew Loblaw, et al.
Clinical Genitourinary Cancer|February 24, 2015
New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?Joyce M van Dodewaard-de Jong, Henk M W Verheul, Haiko J Bloemendal, et al.
Journal of Cancer Survivorship : Research and Practice|February 27, 2015
Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordinationClaire F Snyder, Kevin D Frick, Robert J Herbert, et al.
The Prostate|August 8, 2019
Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtypeEugene Shenderov, Pedro Isaacsson Velho, Anas H Awan, et al.
Annals of Nuclear Medicine|June 1, 2019
Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted <sup>18</sup>F-DCFPyL PET/CTAlexa R Meyer, Michael A Carducci, Samuel R Denmeade, et al.
Pageof 39

Showing results (191-200 of 386) with videos related to

Sort By:
Pageof 39
Urologic Oncology|October 7, 2004
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancerDonald S Kaufman, Michael A Carducci, Tim M Kuzel, et al.
Cancer|September 22, 2007
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerMichael A Carducci, Fred Saad, Per-Anders Abrahamsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion scheduleM A Carducci, J Gilbert, M K Bowling, et al.
Urologic Oncology|September 22, 2014
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)Andrew J Armstrong, Reza Kaboteh, Michael A Carducci, et al.
Prostate Cancer and Prostatic Diseases|February 11, 2010
Does pre-existing diabetes affect prostate cancer prognosis? A systematic reviewC F Snyder, K B Stein, B B Barone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2017
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical OpinionKatherine S Virgo, Ethan Basch, D Andrew Loblaw, et al.
Clinical Genitourinary Cancer|February 24, 2015
New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?Joyce M van Dodewaard-de Jong, Henk M W Verheul, Haiko J Bloemendal, et al.
Journal of Cancer Survivorship : Research and Practice|February 27, 2015
Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordinationClaire F Snyder, Kevin D Frick, Robert J Herbert, et al.
The Prostate|August 8, 2019
Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtypeEugene Shenderov, Pedro Isaacsson Velho, Anas H Awan, et al.
Annals of Nuclear Medicine|June 1, 2019
Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted <sup>18</sup>F-DCFPyL PET/CTAlexa R Meyer, Michael A Carducci, Samuel R Denmeade, et al.
Pageof 39